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Abstract 
Objective To assess pharmacist intervention in 
diabetic patients on patient compliance to medication 
and blood glucose self-monitoring and to evaluate 
patient therapeutic plans through monitoring of glycated 
haemoglobin (HbA1c) levels.
Method Thirty type 2 diabetic patients receiving their 
medication through the Pharmacy of Your Choice (POYC) 
scheme were assessed. Patient compliance to medication and 
to self-blood glucose monitoring was reported before (t=0) 
and following pharmacist intervention (t=1). The pharmacist 
intervention included an educational session and distribution 
of a ‘Diabetes Patient Information Leaflet’. HbA1c testing 
was performed and patients with out-of-range values were 
referred.
Key findings Patient compliance to medication 
improved following pharmacist intervention, with 24 
patients claiming to ‘rarely miss a dose’ of medication prior 
to the intervention (t=0), decreasing to 8 patients at t=1. At 
t=0, 1 patient reported to ‘never miss a dose’ of medication 
which increased to 22 patients at t=1. Fifteen patients 
reported to monitor glucose levels less than once a month 
at t=0, while 23 patients claimed to monitor their glucose 
levels on a weekly basis at t=1. The mean value for HbA1c 
was 6.5%. Two patients obtained HbA1c values of 7.0 and 
7.1% and were referred.
Conclusion Pharmacist-led medication reviews, 
through monitoring of blood glucose and HbA1c levels and 
suggesting optimal pharmacological treatment, can help 
diabetic patients use their medications more effectively to 
achieve maximal treatment benefits. Point-of-care HbA1c 
testing may be an accessible means of assessing glucose control 
and may motivate patients who seek to monitor glycaemia 
more closely.
Keywords Pharmacist intervention, blood 
glucose monitoring, HbA1c testing, diabetes, medication 
compliance.
Introduction
Diabetes poses one of the most significant health 
problems in primary and secondary care sectors in each 
country.1 Locally, diabetes affects around 10% of the 
general population.2  Patients with diabetes commonly 
receive more than one type of medication daily. Complex 
therapeutic plans and possibly a lack of understanding of 
the patient’s pharmacological therapy may lead to lack of 
compliance. 
Patients registered with the POYC scheme may renew 
their prescriptions every two months at government 
clinics where a thorough patient assessment is not always 
undertaken due to time constraints and other factors. This 
situation may lead to over-prescribing. Some patients visit 
different doctors leading to a lack of continuity of treatment 
since their drug history may not always be readily available. 
Another aspect of diabetes management is self-monitoring 
of blood glucose (SMBG). Although blood glucose levels 
should be monitored frequently, patients may find 
themselves monitoring glycaemia only when required or 
when advised to do so by a health care provider.
Glycated haemoglobin (HbA1c) testing is measured primarily 
to identify the average blood glucose concentration over a 
period of time (weeks or months). Values higher than the 
average HbA1c concentration indicate poor blood glucose 
level control. HbA1c monitoring may improve glycaemic 
control and thus treatment outcomes in patients with 
diabetes.3
Locally, HbA1c testing is only performed in one private 
clinic and is recently being carried out free-of-charge at 
Mater Dei hospital laboratory, against private general 
practitioners’ referral. Introduction of point-of-care 
HbA1c testing in community pharmacies or clinics may 
lead to reduced hospital waiting times and support the 
pharmacist in monitoring drug therapy plans. Pharmacist 
intervention plays a key role in educating patients about the 
management of their condition. Close monitoring may lead 
to better control of the condition, both through lifestyle 
changes and pharmacological treatment adjustments 
if necessary. By monitoring blood glucose control in 
relation to patient medication and general patient health, 
pharmacists are in an ideal position to detect medication 
misuse or inappropriateness and discuss such issues with 
prescribers to improve treatment.
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Ethics approval was obtained from the University Research 
Ethics Committee. The study was undertaken at a local 
community pharmacy and 30 patients who were collecting 
their antidiabetic medications through the Pharmacy 
of Your Choice Scheme in the pharmacy were invited to 
participate. Participation in the study was entirely voluntary 
and informed consent was obtained from each patient prior 
the start of the study.
Three tools were used in this study; a previously validated 
‘Patient Questionnaire’4, which was distributed to patients 
at baseline prior to pharmacist intervention (t=0) and 
after 2 months (t=1). This questionnaire, available both in 
English and Maltese language, consisted of multiple-choice 
close-ended questions and an open-ended question. In this 
questionnaire, compliance to medication and blood glucose 
self-monitoring was assessed by self-reporting. A ‘Patient 
Profile Sheet’, including demographic data and medications 
being received, was developed by the investigator (JV) and 
completed at baseline. A ‘Diabetes Patient Information 
Leaflet’, which was also developed by the investigator and 
distributed to patients at baseline, served as an adjunct to 
the pharmacist intervention. An educational session was 
held with the patient in the pharmacy at baseline.
HbA1c testing was carried out in the pharmacy at baseline 
on patients meeting the following inclusion criteria; 
receiving more than 2 medications, undergone recent 
hospital admissions or had treatment modification during 
the past year. Testing was undertaken using the Siemens/
Bayer DCA 2000+® analyser, which gave results within a 
few minutes. Results were discussed with the patients and 
any patients with out-of-range results were referred to a 
physician.
All data was entered into a spreadsheet and results were 
interpreted using SPSS® version 20.0. Statistical tests applied 
included the One-Way ANOVA, Pearson correlation test and 
the Chi-square test. 
Results
Thirty patients participated in this study of which 17 were 
male and 13 were female, all were Maltese and the mean 
age was 67 years (range 57 to 83 years). Patients were 
taking an average of 6 medications, with each patient 
taking an average of 2 antihyperglyaecemic medications. 
The oral antidiabetic drug metformin was being taken by 
20 patients.
Patient compliance to medication improved following 
pharmacist intervention, with 21 patients reporting 
that they rarely miss a dose of medication; this number 
decreased to 3 patients following pharmacist intervention. 
Post intervention patients claimed that they are compliant 
with treatment.
Frequency of glucose monitoring also improved following 
intervention; out of the 3 patients who claimed to check 
glucose levels daily at the end of the study, 2 patients 
reported to do so less than once a month at baseline. Eleven 
patients who checked their glucose levels on less than 
one occasion per month at t=0 reported to monitor their 
levels once a week at t=1. Patient compliance at time 0 was 
compared to frequency of self-blood glucose monitoring 
and there was a trend in less frequent self-monitoring with 
patients who had a higher risk of missing doses (Table 1).
Ten of the participating patients who met inclusion criteria 
were assessed for HbA1c levels. The mean HbA1c value 
obtained was 6.59%. HbA1c (range 5.8 to 7.1%). There was a 
trend in that patients taking a larger number of medications 
obtained higher values for HbA1c compared to those 
who took fewer medications (Figure 1). The two patients 
receiving the largest number of medications in this study 
(11 medications each) had HbA1c values of 6.8% and 7.1% 
respectively. 
Participants who monitored glucose levels daily prior to 
pharmacist intervention were found to have HbA1c values 
of 6.5% or less; those who did so less frequently than once a 
week obtained HbA1c values of 6.65% or greater (Figure 2).
Do you ever miss a dose of medication? (t=0)
No Rarely > once a month Total
How often do 
you check your 
glucose level?
(t=0) 
Once a day 0 2 0 2
Once a week 1 8 0 9
Once a month 0 3 1 4
<Once a month 0 11 4 15
Total 1 24 5 30
Table 1: Patient compliance to medication and frequency of glucose monitoring (n=30)
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Figure 1: Percentage HbA1c and number of medications (n=10)
Discussion
Patient compliance to medication prior to pharmacist 
intervention is considerably low. This result is not surprising 
given the fact that Type 2 diabetes often requires complex 
therapeutic plans, polypharmacy as well as medication 
administration at different times during the day. Some 
patients, may need to split tablets to administer the correct 
dose or eat directly after medication administration, which, 
when performed on a daily basis can be rather demanding. 
The main reason for most patients missing a dose of 
medication on one or more occasions was forgetfulness. 
Pharmacists and other health care professionals should 
continuously educate patients on the importance of 
medication adherence, especially in patients with complex 
treatment regimens for conditions such as diabetes. 
Patients should be made aware of the risks and long-term 
complications that can arise from non-compliance. 
Following pharmacist intervention, most patients 
reported failure to miss a dose of medication and 
compliance to medication improved in the majority 
of participants. Patients need to be educated not only 
about medication regimens but also about the disease 
itself. They should be knowledgeable about the disease 
symptoms, pharmacological management and the 
correct administration of drugs. Incorporating patients 
in treatment discussions is imperative for them to have a 
sound knowledge and understanding of the disease and 
thereby facilitate treatment implementation.
Complex conditions  such as diabetes require multifactorial 
interventions consisting of continuous patient education 
and motivation, together with developing realistic targets 
to improve disease outcome and prevent both micro- and 
macrovascular complications.5
Figure 2: Percentage HbA1c and frequency of glucose monitoring (n=10)
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Following pharmacist intervention, most patients 
reported failure to miss a dose of medication and 
compliance to medication improved in the majority 
of participants. 
Frequency of glucose monitoring was also found to be 
unexpectedly low, with most participants admitting to 
checking their glucose levels less than once a month. 
Regular monitoring of glycaemia is indispensable in optimal 
diabetes management since this cannot be achieved simply 
by correct adherence to medication. Diabetic patients 
should be regularly reminded of the importance of close 
monitoring of glucose levels and advised on the availability 
of various glucose testing devices and their correct use. 
Frequency of glucose monitoring increased following 
pharmacist intervention with most patients reporting 
weekly checking of their glucose levels. However, despite 
the educational session and pharmacist intervention, no 
patients reported checking their glucose levels daily. This 
reflects the tediousness such a task presents to these 
patients, who are additionally required to manage their 
disease daily in other ways. Patients who obtained lower 
values for HbA1c reported better compliance, both to 
medication administration and to glucose monitoring. Such 
results are comparable to those in a study conducted by 
Hansen et al (2009), which showed that lower HbA1c levels 
are associated with more frequent self-monitoring of blood 
glucose. Nonetheless, solely increasing the frequency 
of glucose monitoring does not automatically equate to 
improved HbA1c levels.6
Other factors need to be employed to ensure improvement 
and maintenance of glycaemia. These include dietary 
modifications, executing necessary lifestyle modifications, 
regular check-ups to assess treatment progression and 
continuous monitoring and adherence.
Conclusion
This study attempts to highlight the need of increased 
professional services such as pharmacist interventions, 
which are imperative in conditions such as diabetes. 
Patients who participated in the study showed an overall 
lack of compliance, which improved considerably following 
pharmacist intervention. This emphasises the need for 
improved patient education and closer monitoring to 
ensure improved treatment outcomes. Point-of-care HbA1c 
testing performed within the community pharmacy also 
proved to be important in identifying patients receiving 
sub-optimal treatment and consequently warranting 
referral. Such a service could be a beneficial means of 
monitoring patients’ disease progression more closely, as 
the community pharmacist is one of the most accessible 
healthcare providers.
Increasing awareness of these care issues may improve 
patient perception of diabetes and instil motivation, such 
that patients gain confidence in managing their condition 
better. This will ultimately reflect on an improved disease 
outcome and quality of life of patients and carers.
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